Engineered Biomaterials for Cardiovascular Implants

用于心血管植入物的工程生物材料

• 批准号: 6603581
• 负责人: STEPHEN P MASSIA
• 金额: $ 9.99万
• 依托单位: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6603581
• 关键词: bioengineering /biomedical engineering; biomaterial compatibility; biomaterial development /preparation; biomaterial interface interaction; biomaterials; cardiovascular system; drug delivery systems; gene delivery system; implant; laboratory rat; medical implant science; tissue engineering

DESCRIPTION (provided by applicant): Recent developments in the understanding of the failure of cardiovascular implants has led both the scientific and industrial communities searching for alternatives to provide optimum products. Over the past ten years, rapid advances in cell and molecular biology methodologies have led to a significant expansion of our knowledge base in vascular biology which potentially has application in every area of cardiovascular surgery and implant design. In recognition of the critical role that cell physiology, molecular biology, and other biomedical sciences play in improving implant performance, research and development efforts in cardiovascular implant science and engineering have recently focused on developing engineered biohybrid biomaterials that utilize synthetic biomaterials as well as cells, biochemicals, and extracellular matrix of cardiovascular tissues to develop a new generation of cardiovascular implants and related products that have more specific and longer-term performance goals than products that are currently on the market. The proposed work focuses on developing and applying biohybrid technologies for synthetic vascular grafts. Overall goal of the proposed study: Develop and evaluate the following four biohybrid technologies for improved performance of synthetic vascular grafts using specific implants and animal models currently under investigation by the PI: 1) bioactive biomaterial surface modifications; 2) bioactive degradable hydrogels; and 3) local drug/gene delivery systems and therapies. Hypotheses: The above described b1ohybrid technologies, namely bioactive biomaterial surface modifications, bioactive degradable hydrogels, and local drug/gene delivery system s/therapies will promote significant gains in long-term performance of synthetic vascular grafts. Combinations of these applied technologies will work in synergy to maximize graft performance. Aims: 1) Develop bioactive surface modifications on ePTFE (expanded polytetrafluoroethylene) vascular grafts and assess their effects on implant performance in vivo; 2) Develop degradable hydrogel formulations that can be impregnated into the porous space of ePTFE grafts for promoting angiogenesis in host tissues surrounding the implant, neovascularization of the ePTFE graft wall and luminal endothelialization via transmural growth of neovascular tissue; 3) Develop degradable hydrogel delivery vehicles that can be impregnated into ePTFE grafts for local drug/gene therapies targeting graft hyperplasia; and 4) Compare the impact of combinations of biohybrid technologies on graft performance to single technology approaches. Overall the proposed work will define biohybrid technologies that have promise for clinical application and will set the stage for further technology development. (End of Abstract)

描述（由申请人提供）： 对心血管衰竭认识的最新进展 植入物促使科学界和工业界寻找 提供最佳产品的替代方案。 过去十年，飞速发展 细胞和分子生物学方法学的进步带来了重大进展 扩展我们在血管生物学方面的知识库，这可能具有 应用在心血管手术和植入物设计的各个领域。 在 认识到细胞生理学、分子生物学和 其他生物医学科学在改善植入物性能、研究和 心血管植入科学与工程的发展努力 最近专注于开发工程生物混合生物材料，利用 合成生物材料以及细胞、生化物质和细胞外 心血管组织基质开发新一代心血管 具有更具体和更长期的植入物和相关产品 性能目标优于当前市场上的产品。 这 拟议的工作重点是开发和应用生物混合技术 合成血管移植物。 拟议研究的总体目标：开发和 评估以下四种生物混合技术以提高性能 目前使用特定植入物和动物模型的合成血管移植物 PI正在研究：1）生物活性生物材料表面改性； 2）生物活性可降解水凝胶； 3) 局部药物/基因传递系统和 疗法。 假设：上述 b1ohybrid 技术，即 生物活性生物材料表面修饰、生物活性可降解水凝胶、 本地药物/基因传递系统/疗法将带来显着收益 合成血管移植物的长期性能。 这些的组合 应用技术将协同作用，以最大限度地提高移植性能。 目标： 1) 在 ePTFE（膨胀聚四氟乙烯）上开发生物活性表面改性 聚四氟乙烯）血管移植物并评估其对植入物的影响 体内表现； 2）开发可降解水凝胶配方 浸渍到 ePTFE 移植物的多孔空间中以促进血管生成 在植入物周围的宿主组织中，ePTFE 移植物的新生血管形成 通过新生血管的跨壁生长使血管壁和管腔内皮化 组织; 3）开发可降解的水凝胶递送载体 浸渍到 ePTFE 移植物中，用于针对移植物的局部药物/基因治疗 增生； 4) 比较生物混合组合的影响 技术对单一技术方法的移植性能。 总体而言，拟议的工作将定义有希望的生物混合技术 临床应用并将为进一步的技术奠定基础 发展。 （摘要完）